The Artificial Pancreas Device Market was valued at $1.65 billion in 2025 and is projected to reach $8.93 billion by 2035, growing at a CAGR of 18.40 percent over the 2026 to 2035 forecast period, according to Strategic Revenue Insights. Growth is being driven by the rising global prevalence of diabetes, rapid advances in glucose sensors and control algorithms, government initiatives to improve diabetes care and growing patient demand for automated insulin delivery.
Click here for free sample PDF: https://www.strategicrevenueinsights.com/industry/artificial-pancreas-device-market
Artificial Pancreas Device Market Key Takeaways
- Market size: $1.65 billion in 2025, projected to reach $8.93 billion by 2035 at a CAGR of 18.40 percent.
- Largest device type: threshold suspend device systems; fully closed loop control-to-target systems are the fastest-growing.
- Largest end user: hospitals and clinics, with home care use growing quickly.
- Leading region: North America is the largest market and Asia Pacific is the fastest-growing.
- Key players: Medtronic plc, Insulet Corporation, Tandem Diabetes Care Inc., Dexcom Inc. and Abbott Laboratories.
Artificial Pancreas Device Market at a Glance
| Report Attribute | Details |
|---|---|
| Market size in 2025 | $1.65 billion |
| Projected market size in 2035 | $8.93 billion |
| CAGR (2026 to 2035) | 18.40 percent |
| Historic period | 2018 to 2024 |
| Largest device type | Threshold suspend device systems |
| Fastest-growing device type | Control-to-target (fully closed loop) systems |
| Largest region | North America |
| Fastest-growing region | Asia Pacific |
| Segments covered | Device type, component, treatment type, end user, region |
| Report source | Strategic Revenue Insights (Report ID 91314, 109 pages) |
What Is Driving Artificial Pancreas Device Market Growth
The number of people living with diabetes keeps rising worldwide, and more of them are looking for systems that take the daily burden out of insulin dosing. An artificial pancreas pairs a continuous glucose monitor, an insulin pump and a control algorithm so that insulin delivery adjusts automatically, which improves time in range and reduces dangerous highs and lows.
Advances in sensor accuracy and artificial intelligence are making these systems smaller, more reliable and easier to wear. Government programs to improve diabetes care, broader reimbursement and growing patient awareness of the clinical benefits are accelerating adoption, while manufacturers push toward fully closed loop systems that need little or no manual input.
Segment Insights: Threshold Suspend Systems, Insulin-Only Therapy and Hospitals
By device type, threshold suspend device systems form the largest segment because they were the first automated systems to reach the market at scale. Control-to-range systems sit in the middle, and control-to-target fully closed loop systems are the fastest-growing as algorithms mature and regulators clear more products.
By component, the market covers continuous glucose monitors, insulin pumps and control algorithms and software. Insulin-only systems are the most widely used treatment type, with bihormonal insulin and glucagon systems and adjunctive therapy systems emerging. Hospitals and clinics are the largest end-user group, followed by home care, which is growing as devices become simpler, and diabetes specialty centers.
Regional Dynamics Shaping the Artificial Pancreas Device Market
North America is the largest regional market, supported by a high prevalence of type 1 and type 2 diabetes, strong reimbursement for automated insulin delivery and the presence of leading device makers in the United States.
Asia Pacific is the fastest-growing region as diabetes rates climb sharply in China and India, healthcare spending rises and awareness of advanced diabetes technology spreads. Europe remains an important market with growing national coverage of closed loop systems, while Latin America and the Middle East and Africa offer additional headroom as access improves.
Competitive Landscape
Leading players include Medtronic plc, Insulet Corporation, Tandem Diabetes Care Inc., Dexcom Inc. and Abbott Laboratories. These companies compete on algorithm performance, sensor accuracy, pump form factor and interoperability between monitors, pumps and apps.
Other notable players include Beta Bionics Inc., Ypsomed Holding AG, Roche Holding AG, Sequel Med Tech LLC and Diabeloop SA, which strengthen their positions through bihormonal and fully automated systems, regional partnerships and software innovation.
Opportunities and Challenges Ahead
Opportunities lie in the growing diabetic population and demand for automated insulin delivery with real-time glucose monitoring, continued sensor and AI innovation, and cost-effective systems and new pricing models that open emerging markets.
Challenges include stringent regulatory requirements for closed loop systems and high device costs, which can limit adoption in price-sensitive and emerging markets.
Artificial Pancreas Device Market Outlook to 2035
The Artificial Pancreas Device Market is set to grow more than fivefold by 2035. With personalized medicine, AI-driven algorithms and integrated user-friendly systems shaping care, suppliers that combine clinical accuracy with affordability and strong partnerships are best placed to benefit. Related coverage from Strategic Revenue Insights is available in the Healthcare category on this blog.
Frequently Asked Questions About the Artificial Pancreas Device Market
According to Strategic Revenue Insights, the Artificial Pancreas Device Market was valued at $1.65 billion in 2025 and is projected to reach $8.93 billion by 2035.
The market is expected to grow at a CAGR of 18.40 percent during the 2026 to 2035 forecast period.
Threshold suspend device systems are the largest segment, while control-to-target fully closed loop systems are the fastest-growing. Hospitals and clinics are the largest end users.
Asia Pacific is the fastest-growing region, driven by rising diabetes prevalence and healthcare spending, while North America is the largest market.
Leading companies include Medtronic plc, Insulet Corporation, Tandem Diabetes Care Inc., Dexcom Inc., Abbott Laboratories, Beta Bionics Inc., Ypsomed Holding AG, Roche Holding AG, Sequel Med Tech LLC and Diabeloop SA.
The main challenges are stringent regulatory requirements for closed loop systems and high device costs that limit adoption in emerging markets.
About Strategic Revenue Insights Inc.
Strategic Revenue Insights Inc., a distinguished subsidiary of SRI Consulting Group Ltd, stands as a premier provider of data-driven market intelligence, empowering organizations globally to navigate complex business landscapes with confidence and precision. Headquartered in London, United Kingdom, our firm specializes in delivering comprehensive syndicated research reports, bespoke consulting solutions, and actionable strategic insights that enable clients to make informed, forward-thinking decisions in an increasingly competitive marketplace.
Our dedicated team of accomplished analysts, strategically positioned in London with an extensive global network, maintains continuous vigilance over evolving market dynamics, identifying emerging trends and uncovering high-potential growth opportunities that drive sustained client success. As an integral component of SRI Consulting Group Ltd, we uphold unwavering commitments to analytical accuracy, clarity of presentation, and practical applicability, assisting organizations in navigating competitive terrain, optimizing strategic initiatives, and accelerating revenue trajectories.
Through the integration of rigorous research methodologies with profound industry expertise, Strategic Revenue Insights Inc. delivers comprehensive market perspectives that generate measurable outcomes and establish enduring competitive advantages for our clients across diverse sectors and geographies.
Media Contact Information
Company Name: Strategic Revenue Insights Inc.
Contact Person: Rohit Bhisey
Email: sales@strategicrevenueinsights.com
Phone: +44 7877403352
Address: Suite 10, Capital House, 61 Amhurst Road, E8 1LL
City: London
State: London
Country: United Kingdom
Corporate Websites:
www.strategicrevenueinsights.com
www.strategicpackaginginsights.com
www.sriconsultinggroupltd.com
https://strategicrevenueinsights.blog/
https://www.medium.com/@strategic-revenue-insights.inc
For partnership inquiries, custom research requests, or detailed market analysis consultations, we invite you to connect with our team of experts who are committed to delivering strategic intelligence that transforms business outcomes.